Spots Global Cancer Trial Database for hormone receptor positive tumor

Every month we try and update this database with for hormone receptor positive tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer	NCT00908531	Operable Breast...	letrozole (Fema...	60 Years -	Danish Breast Cancer Cooperative Group
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	NCT01042379	Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance...	Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro...	18 Years -	QuantumLeap Healthcare Collaborative
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer	NCT03874325	Breast Cancer Hormone Recepto...	Durvalumab Anastrozole 1mg Letrozole 2.5mg Exemestane 25 M...	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Dose EScalation Induction of EvERolimus	NCT02387099	Breast Cancer Hormone Recepto...	3 weeks Dose In... 3 weeks Convent... Open Label Phas... Standard Care a...	18 Years -	German Breast Group
Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors	NCT02592083	Early-Stage Bre... Hormone Recepto...	Tamoxifen or Ar... Palbociclib	41 Years -	Karolinska University Hospital
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant	NCT02894398	Breast Cancer Hormone Recepto... Human Epidermal...	Palbociclib Letrozole Anastrozole Exemestane Fulvestrant	18 Years -	iOMEDICO AG
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)	NCT03809988	Breast Cancer Advanced Breast... Hormone Recepto... Human Epidermal...	Palbociclib Endocrine thera...	18 Years -	MedSIR
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	NCT05582499	Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance...	Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC	18 Years - 70 Years	Fudan University
Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer	NCT03904173	Breast Cancer Breast Neoplasm... Hormone Recepto...	Multi-parameter...	18 Years -	Oslo University Hospital
Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA)	NCT04161833	Breast Cancer Hormone Recepto... Arthralgia	OPERA	18 Years -	Azienda Ospedaliero-Universitaria Careggi
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer	NCT04088110	Breast Cancer F... HER2-positive B... Hormone Recepto... Metastatic Brea... Breast Diseases Hormone Recepto...	Pyrotinib Trastuzumab Aromatase Inhib...	18 Years - 70 Years	Fuzhou General Hospital
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer	NCT03917082	Breast Cancer F... Hormone Recepto...	Tamoxifen Citra...	51 Years -	British Columbia Cancer Agency
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors	NCT05759949	PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... Hormone Recepto...	RLY-5836 Fulvestrant Palbociclib Ribociclib Abemaciclib	18 Years -	Relay Therapeutics, Inc.
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer	NCT04352777	Metastatic Brea... Locally Advance... Hormone Recepto...	Abemaciclib Fulvestrant Aromatase Inhib...	18 Years -	Duke University
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer	NCT02404051	Metastatic Brea... Breast Cancer Hormone Recepto... Human Epidermal... Locally Advance...	Everolimus Exemestane Fulvestrant	18 Years -	Consorzio Oncotech
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer	NCT05982093	Breast Cancer HER2-negative B... Hormone Recepto... Premenopausal B...	Elacestrant Triptorelin	35 Years -	SOLTI Breast Cancer Research Group
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)	NCT02730923	Endometrial Car... Metastatic Carc... Hormone Recepto...	AZD2014 Anastrozole	18 Years -	Centre Leon Berard
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer	NCT03409198	Breast Cancer Hormone Recepto... Metastatic Brea...	Ipilimumab Nivolumab Pegylated lipos... Cyclophosphamid...	18 Years -	Oslo University Hospital
Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA)	NCT04161833	Breast Cancer Hormone Recepto... Arthralgia	OPERA	18 Years -	Azienda Ospedaliero-Universitaria Careggi
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer	NCT03874325	Breast Cancer Hormone Recepto...	Durvalumab Anastrozole 1mg Letrozole 2.5mg Exemestane 25 M...	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors	NCT05759949	PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... Hormone Recepto...	RLY-5836 Fulvestrant Palbociclib Ribociclib Abemaciclib	18 Years -	Relay Therapeutics, Inc.
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer	NCT04352777	Metastatic Brea... Locally Advance... Hormone Recepto...	Abemaciclib Fulvestrant Aromatase Inhib...	18 Years -	Duke University
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	NCT05582499	Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance...	Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC	18 Years - 70 Years	Fudan University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: